The Serine/Threonine Protein Kinase/Endoribonuclease IRE1 pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase/Endoribonuclease IRE1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Serine/Threonine Protein Kinase/Endoribonuclease IRE1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Metabolic Disorders, Central Nervous System, and Infectious Disease which include the indications Multiple Myeloma (Kahler Disease), Chronic Lymphocytic Leukemia (CLL), Diabetes, Parkinson’s Disease, Amyotrophic Lateral Sclerosis, and Coronavirus Disease 2019 (COVID-19). It also reviews key players involved in Serine/Threonine Protein Kinase/Endoribonuclease IRE1 targeted therapeutics development with respective active and dormant or discontinued products.
The Serine/Threonine Protein Kinase/Endoribonuclease IRE1 pipeline targets constitutes close to 11 molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 1, 5, and 3 respectively. Similarly, the universities portfolio in Discovery comprises 2 molecule.
Serine/Threonine Protein Kinase/Endoribonuclease IRE1 overview
Serine/Threonine Protein Kinase/Endoribonuclease IRE1, also known as Inositol-Requiring Enzyme 1, is a critical regulator of the unfolded protein response (UPR), a cellular pathway activated in response to endoplasmic reticulum (ER) stress. IRE1 is an ER transmembrane protein that functions as both a kinase and an endoribonuclease, providing a dual mechanism for responding to unfolded or misfolded proteins in the ER lumen. Upon detection of ER stress, IRE1 undergoes autophosphorylation, activating its kinase domain. The activated kinase phosphorylates downstream targets, including itself, as well as the transcription factor X-box binding protein 1 (XBP1). Phosphorylated XBP1 undergoes unconventional splicing by the endoribonuclease activity of IRE1, resulting in the production of a spliced variant that acts as a potent transcription factor. This spliced XBP1 (XBP1s) induces the expression of genes involved in ER-associated degradation (ERAD), protein folding, and other components of the UPR to alleviate ER stress. Beyond its role in the UPR, IRE1 has been implicated in diverse cellular processes, including lipid metabolism, inflammation, and autophagy. Dysregulation of IRE1 signaling is associated with various diseases, including neurodegenerative disorders and cancer.
For a complete picture of Serine/Threonine Protein Kinase/Endoribonuclease IRE1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
